Patent ID: 8669231

Claim:
A method of treating prostate cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a prodrug comprising a therapeutically active drug comprising the thapsigargin derivative 8-O-(12-[L-leucinoylamino]dodecanoyl)-8-O-debutanoylthapsigargin (L12ADT) and a peptide comprising an amino acid sequence having a cleavage site specific for an enzyme having a proteolytic activity of hK2, wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the peptide consists of the amino acid sequence G-K-A-F-R-R (SEQ ID NO: 9), and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of hK2.